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Panic Disorder (PD) is an anxiety disorder characterized by periods of intense and 
uncontrollable fear, often referred to as panic attacks. PD is developed through exposure to panic 
attacks that lead to anxiety and worry about future panic attacks. A vital component of PD is the 
physical nature of the panic symptoms. For this reason, comorbid medical conditions are 
important to analyze. There may be overlap between the symptoms of an individual’s PD and 
medical conditions, or they may exacerbate each other. Individuals with PD are often more 
receptive to interoceptive cues. Consequently, individuals with PD are more likely to interpret 
these interoceptive cues as signals of a medical condition. This review will focus on the 
relationship between PD and medical conditions and analyze the prevalence of comorbidity. 
There has been research on PD comorbidity with respiratory disorders (Meuret, Kroll, & Ritz, 
2017; Muller, Koen, & Stein, 2005), seizure disorder (Muller et al., 2005), Kluver-Bucy 
syndrome (Muller et al., 2005), mitral valve prolapse (Filho et al., 2011; Gulpek et al., 2004; 
Muller et al., 2005), cardiovascular disease (Meuret et al., 2017; Roy-Byrne et al., 2008), 
irritable bowel syndrome (Meuret et al., 2017; Roy-Byrne et al., 2008) and other gastrointestinal 
disorders (Stasi et al., 2017), diabetes (Meuret et al., 2017), fibromyalgia (Carta et al., 2018), 
joint hypermobility (Garcia-Campayo, Asso, & Alda, 2011; Gulpek et al., 2004), and asthma 
(Roy-Byrne et al., 2008). Understanding the relationship between PD and these medical 
conditions is vital for diagnosis and treatment. 
 
 
Characteristics of Panic Disorder 
 A panic attack is an experience of intense fear that can be accompanied by a number of 
physical and mental symptoms, including chest pain, heart palpitations, shortness of breath, 
dizziness, and thoughts of losing control, going crazy, or dying (Bouton, Mineka, & Barlow, 
2001). A person must experience unexpected panic attacks that do not occur because of any cues 
or triggers in order to meet criteria for PD. The individual must also develop substantial anxiety 
or worry about having future panic attacks and the implications of these panic attacks. This is an 
important distinction because many people experience panic attacks in response to stress but do 
not develop anxiety about having panic attacks and therefore do not meet the criteria for a PD 
diagnosis (Bouton et al., 2001). Based on data from the National Comorbidity Survey 
Replication, it is estimated that 4.7% of the U.S. population will experience PD at some time in 
their lives (National Institute of Mental Health, 2017). 
 The physical symptoms associated with panic attacks play a major role in perpetuating 
PD. If an individual with PD experiences breathlessness for any number of reasons they may 
interpret this as the onset of a panic attack. This thought may exacerbate these physical 
symptoms and eventually lead to a panic attack. In an attempt to break this cycle, many 
individuals with PD try to avoid the physical symptoms that occur during their panic attacks. For 
example, an individual may avoid physical exercise because it may cause breathlessness or other 
symptoms that they associate with their panic attacks. This avoidance only helps to maintain the 
PD because the individual does not learn to cope with these physical symptoms. 
 Many of the physical symptoms that occur during panic attacks are also present in the 
medical conditions that will be discussed in this paper. When an individual experiences these 
symptoms it may be difficult for them to determine if it is a representation of their medical 
condition or the onset of a panic attack. The hypersensitivity to physical symptoms that 
individuals with PD exhibit, adds to the complexity of the interaction between these comorbid 
conditions.  
 There is a large body of evidence that anxiety is associated with high rates of medical 
symptoms and increased use of healthcare resources (Katon, Lin, & Kroenke, 2007; Marciniak et 
al., 2005; Simon & VonKorff, 1991). Anxiety disorders are strongly associated with chronic 
medical conditions (Härter, Conway, & Merikangas, 2003; Sareen et al., 2006), indicating the 
importance of research on the connection between anxiety and medical conditions. 
Interoception in Panic Disorder 
 Interoception is defined as the sense of the internal state of the body. Individuals with PD 
have an increased interoceptive sensitivity, or a hypervigilance to physical symptoms. The 
ultimate goal of interoceptive cues is to maintain homeostasis throughout the body, but they are 
also theorized to play a role in feeling emotions (Meuret et al., 2017). For example, the ability of 
an individual to sense their own heartbeat is thought to amplify emotions, specifically sensations 
of anxiety and fear. Individuals that suffer from PD show an increased interoceptive sensitivity 
for somatic symptoms, which makes them more likely to make catastrophic misappraisal about 
their own body sensations (Garfinkel & Critchley, 2013). As previously noted, cardiac symptoms 
are commonly experienced during panic attacks, but are also commonly catastrophized as 
symptoms of a heart attack (Chambless, Beck, Gracely, & Grisham, 2000). For example, an 
individual with PD may experience heart palpitations and jump to the conclusion that they are 
having a heart attack, which in turn increases their panic response. For individuals with a 
comorbid heart condition it may be difficult to differentiate between harmless panic symptoms, 
and symptoms of their heart condition. Several studies have illustrated this hypervigilance to 
panic symptoms. Two studies found that individuals with high anxiety sensitivity and frequent 
panic response were able to perceive their heartrate with greater accuracy than healthy controls 
(Richards & Bertram, 2000; Zoellner & Craske, 1999). Another study revealed that individuals 
with panic attacks were more likely to feel anxious in response to an increase in heartrate, but did 
not differ from controls in the number of heartrate increases (Pauli, Marquardt, Hartl, & 
Nutzinger, 1991). This finding suggests that the subject’s interpretation of their visceral arousal 
is a major component of the panic response cycle.  
Cardiovascular Illness and Panic Disorder 
 Heart palpitations or a “racing heart” is the most widely reported physical symptom of 
panic disorder, which raises suspicions of a link between panic disorder and cardiovascular 
illness. Past research has demonstrated the importance of psychological factors in cardiovascular 
illness, with stressful or traumatic experiences increasing cardiac events. An association has been 
revealed between anxiety disorders and coronary heart disease and hypertension, as well as 
cerebrovascular events, including strokes (Emdin et al., 2016; Meuret et al., 2017; Roy-Byrne et 
al., 2008). Large, nationally representative studies within the United States have found that 
individuals with PD are up to 2 times more likely to be diagnosed with coronary heart disease 
than individuals without PD (Goodwin, Davidson, & Keyes, 2009). There is, however, limited 
research on the role of PD specifically in association with cardiovascular disease. This warrants a 
need for further research that is focused on PD rather than anxiety disorders as a whole. One 
study found an increased rate of PD (13%) in hypertensive primary care patients, in which the 
PD developed after the hypertension diagnosis (Davies et al., 1999). More research is needed to 
determine the timeline of diagnoses among other cardiovascular illnesses and PD. A treatment 
for life-threatening ventricular fibrillations, implantable cardioverter defibrillators, delivers 
shock to the individual. This treatment, although effective, has negative psychological outcomes 
including PD. One study found that within individuals undergoing this treatment and 
experiencing more than two electrical shocks per year, the prevalence of PD with agoraphobia 
was 62% (Meuret et al., 2017). Within individuals that only experienced one electrical discharge 
per year, the prevalence rate of PD with agoraphobia was 10%. Several studies have 
demonstrated that PD patients have an increased risk of developing various cardiovascular 
illnesses including a 1.3-fold risk of developing hypertension (Stein et al., 2014), a 1.5-fold risk 
of atrial fibrillation (Cheng et al., 2013), and a fourfold risk of developing coronary heart disease 
(Smoller et al., 2007).  
 There are several mechanisms that may play a role in the link between PD and 
cardiovascular illnesses. Problematic health behaviors that are often present in individuals with 
PD have been discussed as a contributor to this link, including lack of physical activity, obesity, 
and smoking (Meuret et al., 2017). Prescriptions of selective serotonin reuptake inhibitors that 
are often given to patients with PD can contribute to obesity and subsequent development of 
cardiovascular illnesses. There are also pathways in which cardiovascular illness may lead to 
subsequent development of PD. The emotional consequences of cardiovascular illness, including 
catastrophic thoughts and fear of dying, may lead to a development of anxiety or PD in 
individuals that are susceptible (Meuret et al., 2017). As discussed earlier, cardioverter 
defibrillator treatment can also increase the likelihood for an individual to develop PD. Although 
this treatment may be effective, the side effect of developing PD may cause patients to 
discontinue treatment. Understanding the link between PD and cardiovascular illness, and the 
mechanisms that are involved, is vital to the development of effective treatments.  
 
Respiratory Conditions and Panic Disorder 
 Individuals with asthma have an increased prevalence rate of PD. A range of samples 
have suggested that the comorbidity rate is between 7% and 45% (Meuret et al., 2017). This 
clearly identifies a need for further research to more accurately define the prevalence of 
comorbidity between PD and asthma. Among pediatric patients (aged 5 to 11) with asthma the 
prevalence rate of comorbid PD was 14.9%, with other anxiety disorders following behind with a 
prevalence rate of 8.1% for separation anxiety, 5.4% for agoraphobia, and 4.1% for generalized 
anxiety disorder (Goodwin et al., 2009). Although asthma is the most commonly researched, PD 
is associated with an elevated prevalence of respiratory disease in general, including chronic 
bronchitis, COPD, and emphysema. However, this elevation in the rate of comorbidity is also 
seen in other mental illnesses including major depression, social anxiety disorder, and substance 
abuse (Patten & Williams, 2007).  
 Research has revealed that the association between PD and respiratory illness is 
bidirectional. Respiratory illness during childhood leads to an increased risk of PD diagnosis 
later in life. For example, one study found that asthma during early adulthood was associated 
with the development of PD 20 years later (Hasler, Gergen, Kleinbaum, Ajdacic, & al, 2005). 
This same study also found that PD during early adulthood was associated with developing 
asthma later in life. These findings support the bidirectional association between PD and 
respiratory illness, but it is important to understand the mechanisms that underlie this 
association.  
 Similar mechanisms that play a role in cardiovascular illness comorbidity, may also play 
a role in the comorbidity between PD and respiratory conditions. As described above, 
problematic health behaviors including lack of physical activity, obesity, and smoking are also 
relevant to respiratory illnesses. For example, individuals with PD often avoid exercise due to the 
uncomfortable physical symptoms, but this exercise avoidance not only exacerbates the PD it 
also increases the risk of respiratory complications due to a sedentary lifestyle (Lucas & Platts-
Mills, 2005). Smoking and obesity contribute to this increase in risk by causing airway damage 
and inflammation (Lugogo, Kraft, & Dixon, 2009).  Sustained states of stress and anxiety can 
also generate inflamed airways, which can be exacerbated by anticipatory anxiety about future 
attacks (Battaglia & Ogliari, 2005). Anxiety and stress can facilitate respiratory infections as 
well, which can lead to the development of a respiratory illness.  
 There are several mechanisms in which respiratory illness can lead to subsequent PD. 
The emotional burden of chronic illness can lead to stress, anxiety, and even catastrophizing that 
may contribute to the development of PD. The symptoms that are associated with respiratory 
illness may be misinterpreted. For example, breathlessness is a common symptom among 
respiratory illnesses and is also one of the most common symptoms associated with PD. 
Individuals with respiratory illnesses may also be more attuned to a suffocation alarm that can 
lead to hyperventilation, which is also common in PD (Klein, 1993). Several medications for 
respiratory illness, including bronchodilators and oral corticosteroids, can induce symptoms 
similar to those observed during the onset of a panic attack (Brown et al., 2004; Lehrer et al., 
2008). 
Functional Gastrointestinal Disorders and Panic Disorder 
 There are 28 functional gastrointestinal disorders (FGIDs), of which irritable bowel 
syndrome (IBS) is the most common and well-studied (Roy-Byrne et al., 2008). Individuals with 
IBS typically have visceral hyperalgesia, an exaggerated pain response to intestinal activity 
(Drossman, 2006; Jarcho & Mayer, 2007). Similar to the increase in interoception that is seen in 
PD, individuals with IBS have an increased awareness of digestive discomfort. Stress reactivity 
is also an important feature of IBS (Drossman, 2006; Jarcho & Mayer, 2007) and is characteristic 
of many anxiety and mood disorders. IBS is associated with higher levels of neuroticism, anxiety 
sensitivity, visceral anxiety, and worry compared to those without IBS (Hazlett-Stevens, Craske, 
Mayer, Chang, & Naliboff, 2003). IBS has high rates of comorbidity with other illnesses, 
suggesting that individuals with IBS are hypervigilant to symptoms (Whitehead et al., 2007). IBS 
has been linked to PD, with individuals with IBS having a prevalence rate for PD between 3.8% 
and 31% (Walker, Roy-Byrne, & Katon, 1990), although a more recent study has estimated that 
4.4% of individuals with IBS also have a comorbid PD diagnosis (Janssens, Zijlema, Joustra, & 
Rosmalen, 2015). More research is needed to get a more accurate prevalence rate, but it is clear 
that among individuals with PD the rate of IBS is over twice that of those without PD (Lydiard, 
2005).  
 Visceral pain signals, stress response, mood, anxiety, and gastrointestinal function are 
processed within the same neural pathways (Grundy et al., 2006), suggesting that these pathways 
may play a role in the comorbidity between PD and IBS. The hypothalamic-pituitary-adrenal 
(HPA) axis and subsequent corticotropin-releasing factor (CRF) play a major role in these 
pathways (Roy-Byrne et al., 2008). Severe or prolonged stress can lead to CRF hyperactivity and 
the release of pro-inflammatory cytokines and catecholamines, which can result in excessive 
inflammatory activity (Chang, 2006; Dinan et al., 2006). There is evidence for HPA 
abnormalities and pro-inflammatory activity in IBS and PD, suggesting that CRF dysregulation 
may act as a link between the two disorders (Chang, 2006). IBS and PD have similar 
mechanisms of onset and symptoms including anticipatory anxiety, nausea, and abdominal 
distress (Meuret et al., 2017). Patients with IBS and patients with PD have similar illness 
prognoses, while individuals that have both have exacerbated versions of each disorder. One 
study found that anticipatory anxiety was higher in comorbid patients than in patients with PD 
alone (Sugaya et al., 2013). Catastrophic interpretations of IBS symptoms may contribute to PD 
development or maintenance (Meuret et al., 2017). Because IBS and PD have overlapping 
symptoms and mechanisms, they can both be treated with antidepressants, anxiolytics, and 
cognitive-behavioral therapy (Roy-Byrne et al., 2008).  
Chronic Pain and Panic Disorder 
 Pain is a perceptual experience that can be altered by a number of factors including 
cognition, emotion, behavior, and social influences. Pain is designed as an adaptive process to 
avoid physical harm, but chronic pain no longer provides this adaptive quality (Roy-Byrne et al., 
2008). The most common chronic pain disorders include chronic spinal pain, rheumatoid 
arthritis, fibromyalgia, and migraines. Chronic pain can lead to a slew of emotional distress 
including anger, guilt, depression, fear, social withdrawal, and anxiety (McWilliams, Cox, & 
Enns, 2003). These emotions can contribute to the experience of chronic pain, and chronic pain 
patients have higher rates of anxiety symptoms, specifically panic symptoms (Means‐
Christensen, Roy‐Byrne, Sherbourne, Craske, & Stein, 2008). In two National Comorbidity 
Surveys the percentage of chronic pain patients with comorbid PD was 4.8% and 6.5% 
(McWilliams et al., 2003; Von Korff et al., 2005). Comorbidity rates are particularly high in 
chronic pain patients that experience chest pain or negative cardiac symptoms (Beitman et al., 
1989; Katon et al., 2007). It is unclear whether PD typically precedes chronic pain or vice versa. 
Within a population of 146 injured workers with chronic pain, all but one of the patients had an 
anxiety disorder before the onset of their chronic pain (Asmundson, Jacobson, Allerdings, & 
Norton, 1996). Another study with a sample of 90 chronic lower back pain patients found that 
23% of the patients previously had an anxiety disorder (Kinney, Gatchel, Polatin, Fogarty, & 
Mayer, 1993). More research is needed to determine the temporal pattern between chronic pain 
and PD specifically.  
 Pain and fear are both associated with physiological arousal. They are adaptive 
mechanisms, but can have detrimental effects when prolonged (Roy-Byrne et al., 2008). There is 
some literature to support the use of cognitive-behavioral therapy for individuals with chronic 
pain (Devine EC, 2003; Hoffman, Papas, Chatkoff, & Kerns, 2007; Morley, Eccleston, & 
Williams, 1999). Graded exposure has been used to reduce fear and pain intensity, and to 
increase physical activity in individuals with chronic pain (de Jong, Vlaeyen, Onghena, Cuypers, 
et al., 2005; de Jong, Vlaeyen, Onghena, Goossens, et al., 2005; Woods & Asmundson, 2008). 
Antidepressants are also beneficial to chronic pain patients (Saarto & Wiffen, 2007). These 
treatments are promising for individuals with comorbid PD and chronic pain, due to the overlap 
in effective treatment methods. 
Diabetes and Panic Disorder 
 Within diabetic patient samples 1.3% to 8.9% have comorbid PD (Fisher et al., 2008; 
Grigsby, Anderson, Freedland, Clouse, & Lustman, 2002). However, one study found that the 
prevalence of PD is higher among patients with Type I diabetes than patients with Type II 
diabetes (de Ornelas Maia, Braga, Brouwers, Nardi, & de Oliveira e Silva, 2012). Individuals 
with diabetes and a comorbid PD or anxiety disorder exhibit poorer blood glucose levels and an 
increase in pain, symptom burden, diabetic complications, and overall disability (Smith et al., 
2013).  
PD and diabetes have a considerable amount of symptom overlap. One potential 
mechanism of the bidirectional association of PD and diabetes is the hypoglycemic episodes that 
mimic panic symptoms and can lead to a conditioned fear response. During a hypoglycemic 
episode an individual may feel faint, a symptom that is also characteristic of PD. This can lead to 
a panic response and subsequently a conditioned fear response. One survey of 244 diabetic 
patients who have experiences hypoglycemic episodes found that 74% were also diagnosed with 
agoraphobia, a conditioned fear response (Costea, Ionescu-Tîrgovişte, Cheţa, & Mincu, 1993). 
The conditioned fear response contributes to both the development and maintenance of panic. 
HPA axis dysregulation may be a mechanism for the comorbidity of PD and diabetes (Meuret et 
al., 2015). HPA axis activation without the presence of a threatening stimuli is characteristic of 
PD, and can lead to elevated levels of glucocorticoids, which initiates insulin resistance that is 
seen in diabetes (Rafacho, Ortsäter, Nadal, & Quesada, 2014).  Negative health behaviors that 
are associated with PD may have an influence on the development and maintenance of diabetes. 
These include sedentary behavior, obesity, smoking, and poor sleep (DeFronzo et al., 2015). 
Mitral Valve Prolapse and Panic Disorder 
 The association between mitral valve prolapse and panic disorder is debated within the 
research community because there are mixed results of the prevalence rate of the comorbid 
disorders. Mitral valve prolapse is an abnormality, affecting 3% to 5% of the adult population 
(Devereux, 1995; Freed et al., 1999), in which the two flaps of the mitral valve do not close 
evenly. Mitral valve prolapse and PD share many symptoms including chest pain, palpitations, 
dyspnea, dizziness, fatigue, and anxiety, and are both more common in women (Gulpek et al., 
2004). Some studies suggest that the rate of mitral valve prolapse in PD is as great as 20% to 
50% (Muller et al., 2005). A more recent study, with a sample size of 50, found no significant 
difference in prevalence rate with 2.4% of PD patients also diagnosed with mitral valve prolapse 
and only 1% of the control group diagnosed with mitral valve prolapse (Filho et al., 2011). There 
is a need for more research on the prevalence of PD and mitral valve prolapse with larger sample 
sizes and a more standardized criterion for mitral valve prolapse diagnosis. PD and mitral valve 
prolapse may both be affected by dysregulation of the autonomic nervous system, including an 
increase in heart rate variability (Sullivan et al., 2004; Yeragani, Tancer, & Uhde, 2003). PD 
treatments have been found to be effective for mitral valve prolapse by reducing symptoms like 
hyperventilation that can contribute to heart rate variability (Sullivan et al., 2004).  
Joint Hypermobility Syndrome and Panic Disorder 
 Joint hypermobility syndrome is a common, hereditary, connective tissue disorder that 
has been associated with PD and mitral valve prolapse (Garcia-Campayo et al., 2011; Muller et 
al., 2005). One of the first studies to look at the association between joint hypermobility and PD 
found that 67.7% of PD patients also had joint hypermobility syndrome (Martin-Santos, 
Bulbena, Porta, Gago, & al, 1998). Unlike other comorbid conditions, the temporal sequence is 
obvious because joint hypermobility syndrome is present from early childhood, while PD does 
not typically develop until early adulthood (Garcia-Campayo et al., 2011). One study aimed at 
understanding the role of mitral valve prolapse in the association of PD and joint hypermobility 
syndrome found that joint hypermobility syndrome was found in 59.5% of PD patients with 
mitral valve prolapse, and in 42.9% of PD patients who did not have mitral valve prolapse 
(Gulpek et al., 2004). This study suggests that mitral valve prolapse affects the prevalence of 
joint hypermobility syndrome in PD patients. Many of the symptoms and disorders discussed in 
this paper are also associated with joint hypermobility including asthma, cardiac dysfunctions, 
digestive problems, and pain disorders (Garcia-Campayo et al., 2011). The only suggested 
mechanism for the association between joint hypermobility syndrome and PD is a genetic 
mutation, DUP25, on chromosome 15 that has been significantly associated with PD, social 
anxiety disorder, and joint hypermobility disorder (Gratacòs et al., 2001). However, another 
study did not find DUP25 in any of their patients with joint hypermobility syndrome and PD 
(Tabiner et al., 2003). More research is needed to determine the mechanisms that contribute to 
the association between joint hypermobility syndrome and PD. 
Diagnosis and Treatment Implications 
  The overlap of symptoms between PD and comorbid medical conditions may cause errors 
in diagnosis and treatment, which may lead to additional healthcare costs (Greenberg et al., 
1999; Potokar & Nutt, 2000). At the onset of symptoms many individuals turn to primary care 
settings where there is limited time and resources for comprehensive testing. Healthcare 
professionals may also overlook comorbid disorders after one diagnosis is made based on the 
presented symptoms (Meuret et al., 2017). Not only is there a bidirectional association between 
PD and medical conditions, but they can also exacerbate one another. For example, asthma is 
exacerbated by the presence of comorbid PD, this exacerbated asthma subsequently leads to 
symptoms that are feared by PD patients and therefore exacerbate the panic attacks that PD 
patients experience (Meuret, Ehrenreich, Pincus, & Ritz, 2006).  
 Comorbid treatment poses a challenge as treatment of one disorder may exacerbate the 
other disorder. Cognitive-behavioral therapy, that is often used to treat PD, includes voluntarily 
experiencing the symptoms of a panic attack which may cause issues for individuals with a 
comorbid medical illness. For a patient with comorbid PD and respiratory illness, it would be 
problematic to use cognitive behavioral therapy that requires voluntary hyperventilation because 
this would induce bronchoconstriction (Meuret et al., 2006). Cognitive-behavioral therapy may 
be an effective treatment many comorbid PD and medical conditions. The breathing exercises 
that are often taught during cognitive-behavioral therapy are beneficial for individuals with 
comorbid respiratory illnesses because they can teach individuals how to reduce hyperventilation 
(Meuret, Wilhelm, Ritz, & Roth, 2008).  
Future Research 
 There is still much to be discovered about the association between PD and medical 
conditions. Further research with larger sample sizes is needed to pin down more accurate 
prevalence rates for the comorbid disorders. Longitudinal studies are necessary to determine the 
temporal sequence of disorder onsets. Understanding which disorder preceded the other may 
help elucidate the mechanisms of onset. There is a need for neurological studies to determine the 
pathways that are involved in PD and the comorbid medical condition. Examining biological 
mechanisms will also help to illuminate the factors that contribute to this onset of conditions. 
There is little research on treatment for these comorbid disorders. Treatments are typically aimed 
at one of the comorbid disorders but ignores the other. Cognitive-behavioral therapy is effective 
for treating PD and some medical conditions but must be adapted to treat other medical 
conditions. Therapies and medications that are useful in treating PD must be evaluated as 
treatments for the comorbid medical illnesses. There is also a need for a more effective method 
of diagnosing these comorbid conditions. Many of these illnesses go undiagnosed because one 
diagnosis is already determined. More research is needed to understand the complex interaction 




  Panic disorder has a complex array of comorbid medical conditions with an 
overlap in symptoms and mechanisms of onset. The physical nature of PD contributes to the 
hypervigilance towards physical symptoms that may overlap with comorbid medical illnesses. 
PD patients often interpret their physical symptoms as dangerous, especially if they are 
symptoms that overlap with their medical condition. It is important for PD patients, as well as 
their healthcare professionals, to parse out symptoms that are panic related and symptoms that 
are due to their medical illness. Our understanding of PD and comorbid medical conditions is 
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